Compare STNE & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STNE | SRPT |
|---|---|---|
| Founded | 2012 | 1980 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2018 | 2000 |
| Metric | STNE | SRPT |
|---|---|---|
| Price | $9.32 | $18.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 29 |
| Target Price | $19.07 | ★ $25.85 |
| AVG Volume (30 Days) | ★ 5.3M | 3.0M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.99 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $15.07 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | ★ N/A | $6.15 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $9.08 | $14.68 |
| 52 Week High | $19.95 | $25.32 |
| Indicator | STNE | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 43.84 |
| Support Level | $9.27 | $15.40 |
| Resistance Level | $11.58 | $23.80 |
| Average True Range (ATR) | 0.37 | 1.30 |
| MACD | -0.04 | -0.41 |
| Stochastic Oscillator | 21.10 | 13.06 |
StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. The brands of the company include: Stone: For small and medium-sized businesses, all management is integrated with the payment terminal, business bank account, and card, all within the same app. Ton: For micro-entrepreneurs and freelancers, modern card machines, sales via Pix or TapTon, and a Super Account. Stone pagar.me for those who sell online. Digital payment technology for all types of businesses.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.